Matt is the Chief Operating Officer for the Generative Biology Institute (GBI) at EIT, where he is currently leading on the set up of GBI ahead of launch later this year.

Prior to this role, Matt worked closely with GBI's Founding Director, Jason Chin, on the formation of Constructive Bio Ltd, a spin-out from MRC-LMB, where Matt served as a Director from inception until the completion of its Series A in September 2024. Together they worked closely to recruit the founding team, license the underlying IP, and establish operations.

In addition, Matt has held several Non-Executive roles in within medical and scientific research, including as Chair of Kidney Research UK, Non-Executive Director of the Wellcome Sanger Institute, and previously as Chair of Prostate Cancer Research.

Before moving into research, Matt worked in investment banking for 15 years, advising on over $300bn of mergers and acquisitions for some of the largest companies in the UK including the acquisition of Sky by Comcast, the sale of BG Group to Shell, and the defence of AstraZeneca from a hostile approach from Pfizer. Matt holds a degree in Mathematics from the University of Cambridge.

‍

‍

‍